BioAffinity Technologies shares surged 63.55% after the company secured a Hong Kong patent covering platform technology for its CyPath Lung diagnostic. The grant complements a China patent issued in 2025 and expands the company’s intellectual-property protection in a region accounting for nearly two-thirds of global lung cancer cases, or about 1.6 million annually. CyPath Lung uses flow cytometry and fluorescent markers to identify malignant cells in patient sputum. BioAffinity says clinical trials showed 92% sensitivity, 87% specificity, 88% accuracy and a 99% negative predictive value when assessing indeterminate lung nodules under 20 millimeters. The diagnostic is marketed as a CLIA-regulated laboratory-developed test and is protected across the United States, Europe, Japan, China and Hong Kong. An earlier report put the stock’s gain at 50.47%, with shares at $8.05, while the latest update cited a 63.55% increase.